Dedicated exclusively to animal health for over fifty years, Virbac aims to continue its development in harmony with its environment and with its workers. It also wants to ensure the continuity of the Group through sustainable and profitable growth. In 2017, Virbac showed slightly lower organic growth (-0.5%). This reflects a contrasting situation with, on the one hand, strong growth outside the United States, particularly in developing countries, and on the other hand, a drop in the United States, where the recovery has been slower than planned.
As part of its strategy, Virbac supports its development through regular new product launches, the strength of its large portfolio and a global presence reaching into all the major markets in both developed and developing countries. Virbac also benefits from a stable shareholder family that favors constant and long-term growth over short-term goals. In terms of sub-contracted production activities (licensing products or production sub-contracted to a third party), they account for more than a third of the Group's revenue in 2017, as a result of the acquisition of Sentinel products manufactured externally over the period. The suppliers in charge of manufacturing these products are managed according to the assessment procedures described in the G4-HR5 and G4-HR10 indicators.
Change in revenue (in € million) and Group workforce
Change in net profit and market capitalization (in € million)
Virbac pursues a policy of investment and innovation that ensures the continuity and independence of the company. Also, Virbac independently sustains its internal and external growth. The resources thus identified support funding for innovation that is geared towards meeting the needs of customers.
In 2017, resources dedicated to innovation (research, development, licensing) accounted for 8.4% of its revenue.
|R&D expenses + Licensing
|Net debt / equity -
Group share (%)